Get the Stockscreener App
284.39
1.62%
-4.69
Abbvie Inc stock is traded at $284.39, with a volume of 2.65M.
It is down -1.62% in the last 24 hours and up +7.53% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$289.08
Open:
$287.63
24h Volume:
2.65M
Relative Volume:
0.47
Market Cap:
$502.55B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
140.27
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.32%
1M Performance:
+7.53%
6M Performance:
+38.65%
1Y Performance:
+22.91%
1-Day Range:
$282.15
$289.00
1-Week Range:
$282.59
$291.40
52-Week Range:
$190.75
$291.40
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
284.39 | 502.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,275.84 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.20 | 619.84B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
149.84 | 369.68B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.09 | 292.88B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290 - ad-hoc-news.de
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
AbbVie Inc. (ABBV80.BK) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts - Yahoo Finance
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - The Globe and Mail
AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05 - ad-hoc-news.de
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying? - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
AbbVie ABBV-466 Achieves 40.5% Crohn's Remission - grafa.com
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - TradingView
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - TradingView
AbbVie (ABBV) Reports Promising Phase 2a Data for ABBV-466 in Cr - GuruFocus
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It - The Motley Fool
AbbVie (ABBV) to Showcase Expanded Solid Tumor Research at ESMO Congress - GuruFocus
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors? - Yahoo Finance
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - Yahoo Finance
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - The Motley Fool
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance
5 Stock Ideas for Your Short List - TradingView
5 Stock Ideas for Your Short List - Zacks Investment Research
Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00 - ad-hoc-news.de
AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance
Form 4 AbbVie Inc For: 16 October By Investing.com - Investing.com Nigeria
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands - Yahoo Finance
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
Abbvie Inc. Announces Appointment of John M. Carethers as Director and Member of Public Policy and Sustainability Committee - www.marketscreener.com
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF - The Motley Fool
Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot - Bloomberg Law News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
AbbVie’s Q3 2026 Earnings: What to Expect - Barchart.com
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today. - Barron's
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis - TradingKey
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbvie Inc Stock (ABBV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
| NICHOLAS DONOGHOE | Officer |
Aug 14 '26 |
Proposed Sale |
250.00 |
32,710 |
8,177,500 |
0 |
| ROBERT J ALPERN | Director |
May 26 '26 |
Proposed Sale |
214.00 |
13,000 |
2,781,991 |
0 |
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
| David R. Purdue | Officer |
Mar 04 '26 |
Proposed Sale |
233.56 |
5,230 |
1,221,519 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
234.39 |
18,668 |
4,375,549 |
4,619 |
| PERRY C SIATIS | Officer |
Mar 02 '26 |
Proposed Sale |
234.39 |
18,668 |
4,375,585 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Option Exercise |
172.62 |
22,381 |
3,863,458 |
60,518 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Sale |
230.00 |
22,381 |
5,147,630 |
38,137 |
| PERRY C SIATIS | Officer |
Feb 25 '26 |
Proposed Sale |
230.00 |
22,381 |
5,147,630 |
0 |
0.81%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):